Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension

Aliskiren is the first in a new class of direct renin inhibitors to be approved for the treatment of hypertension. In this double-blind, multicentre trial, 694 patients with hypertension (mean sitting diastolic blood pressure [BP] > or = 95 and < 110 mmHg) were randomised to once-daily aliskir...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the renin-angiotensin-aldosterone system 2008-09, Vol.9 (3), p.163
Hauptverfasser:	Dietz, Rainer, Dechend, Ralf, Yu, Chuek-Man, Bheda, Manesh, Ford, Jessica, Prescott, Margaret F, Keefe, Deborah L
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Amides - administration & dosage Amides - adverse effects Amides - pharmacology Amides - therapeutic use Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Atenolol - administration & dosage Atenolol - adverse effects Atenolol - therapeutic use Blood Pressure - drug effects Demography Diastole - drug effects Drug Therapy, Combination Endpoint Determination Female Fumarates - administration & dosage Fumarates - adverse effects Fumarates - pharmacology Fumarates - therapeutic use Heart Rate - drug effects Humans Hypertension - drug therapy Hypertension - physiopathology Male Renin - antagonists & inhibitors Renin - blood Renin-Angiotensin System - drug effects Systole - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!